|
|
Blood, 1 November 2005, Vol. 106, No. 9, pp. 2982-2991.
Prepublished online as a Blood First Edition Paper on August 2, 2005; DOI 10.1182/blood-2005-04-1543.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome
Alexander Sternberg,
Sally Killick,
Tim Littlewood,
Chris Hatton,
Andy Peniket,
Thomas Seidl,
Shamit Soneji,
Joanne Leach,
David Bowen,
Claire Chapman,
Graham Standen,
Edwin Massey,
Lisa Robinson,
Bipin Vadher,
Richard Kaczmarski,
Riaz Janmohammed,
Kim Clipsham,
Andrew Carr, and
Paresh Vyas
From the Department of Haematology, Weatherall Institute of Molecular Medicine and John Radcliffe Hospital, Oxford, United Kingdom; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom; Royal Bournemouth Hospital, United Kingdom; Institute of Cancer Research, London, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Leicester Royal Infirmary, United Kingdom; Bristol Royal Infirmary, United Kingdom; Hereford County Hospital, Hereford, United Kingdom; Princess Alexandra Hospital, Farnborough, United Kingdom; Hillingdon Hospital, London, United Kingdom; and Nuffield Orthopaedic Centre, Oxford, United Kingdom.
Early, low-risk International Prognostic Scoring System (IPSS) myelodysplastic syndrome (MDS) is a heterogeneous disorder where the molecular and cellular hematopoietic defects are poorly understood. To gain insight into this condition, we analyzed gene expression profiles of marrow CD34+ progenitor cells from normal-karyotype, low-blast-count MDS patients, age-matched controls, and patients with non-MDS anemia. Given the heterogeneity of early MDS, a surprisingly consistent finding was decreased expression of B-cell lineage–affiliated genes in MDS patients compared with healthy controls and 3 of 5 samples with non-MDS anemia. Both patients with non-MDS anemia with reduced B-cell gene expression were on chemotherapy. In 25 of 27 of the original samples and 9 further MDS samples, Taqman real-time polymerase chain reaction (PCR) confirmed these data. Flow cytometry on unfractionated marrow from independent samples also demonstrated reduced B-cell progenitors in MDS patients compared with healthy controls. These novel findings suggest a common perturbation in early MDS hematopoiesis. They also provide the rationale for a larger study to evaluate the diagnostic utility of reduced B-cell progenitor number as a diagnostic biomarker of early low-risk MDS, which can pose a diagnostic challenge.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. L. Chen, T. D. Logan, M. L. Hochberg, S. G. Shelat, X. Yu, G. E. Wilding, W. Tan, G. C. Kujoth, T. A. Prolla, M. A. Selak, et al.
Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction
Blood,
November 5, 2009;
114(19):
4045 - 4053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Sutton, M. Vusirikala, and W. Chen
Hematogone Hyperplasia in Copper Deficiency
Am J Clin Pathol,
August 1, 2009;
132(2):
191 - 199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Goardon, E. Nikolousis, A. Sternberg, W.-K. Chu, C. Craddock, P. Richardson, R. Benson, M. Drayson, G. Standen, P. Vyas, et al.
Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes
Haematologica,
August 1, 2009;
94(8):
1160 - 1163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. van de Loosdrecht, C. Alhan, M. C. Bene, M. G. Della Porta, A. M. Drager, J. Feuillard, P. Font, U. Germing, D. Haase, C. H. Homburg, et al.
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
Haematologica,
August 1, 2009;
94(8):
1124 - 1134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Zhou, A. N. Nguyen, D. Sohal, J. Ying Ma, P. Pahanish, K. Gundabolu, J. Hayman, A. Chubak, Y. Mo, T. D. Bhagat, et al.
Inhibition of the TGF-{beta} receptor I kinase promotes hematopoiesis in MDS
Blood,
October 15, 2008;
112(8):
3434 - 3443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. van de Loosdrecht, T. M. Westers, A. H. Westra, A. M. Drager, V. H. J. van der Velden, and G. J. Ossenkoppele
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry
Blood,
February 1, 2008;
111(3):
1067 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ogata, Y. Kishikawa, C. Satoh, H. Tamura, K. Dan, and A. Hayashi
Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes
Blood,
August 1, 2006;
108(3):
1037 - 1044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pellagatti, M. Cazzola, A. A. N. Giagounidis, L. Malcovati, M. G. D. Porta, S. Killick, L. J. Campbell, L. Wang, C. F. Langford, C. Fidler, et al.
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype
Blood,
July 1, 2006;
108(1):
337 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
